NASDAQ:STIMNeuronetics Stock Price, Forecast & News

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STIM shares have decreased by 2.4% and is now trading at $2.02. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics.

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Neuronetics.

Neuronetics Inc (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.13. The company earned $11.48 million during the quarter. Neuronetics had a negative return on equity of 68.77% and a negative net margin of 55.58%. View Neuronetics' earnings history.

Neuronetics issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $11.8-12 million, compared to the consensus revenue estimate of $13.77 million.

4 Wall Street analysts have issued 1 year price targets for Neuronetics' stock. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next year. This suggests a possible upside of 164.0% from the stock's current price. View analysts' price targets for Neuronetics.

News stories about STIM stock have been trending very negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNeuronetics.

Neuronetics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 704,900 shares, an increase of 10.3% from the April 30th total of 639,000 shares. Based on an average daily trading volume, of 322,400 shares, the days-to-cover ratio is currently 2.2 days. Approximately 6.6% of the company's stock are sold short. View Neuronetics' Current Options Chain.

Some companies that are related to Neuronetics include Restoration Robotics (HAIR), BeyondAirInc . (XAIR), PAVmed (PAVM), Venus Concept (VERO), Spectral Medical (EDTXF), SANUWAVE Health (SNWV), Pro-Dex (PDEX), AIT Therapeutics (AITB), BRAINSWAY LTD/S (BWAY), Nephros (NEPH), Nephros (NEPHD), Titan Medical (TMDI), Sensus Healthcare (SRTS), Neovasc (NVCN) and STRATA Skin Sciences (SSKN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Nokia Oyj (NOK), Novavax (NVAX) and Onconova Therapeutics (ONTX).

(STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.81%), DAFNA Capital Management LLC (2.65%), Quinn Opportunity Partners LLC (2.55%), State Street Corp (1.24%), Two Sigma Investments LP (1.10%) and JPMorgan Chase & Co. (1.03%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger and William Andrew Macan. View institutional ownership trends for Neuronetics.

STIM stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Alambic Investment Management L.P., Deutsche Bank AG, and Spark Investment Management LLC. View insider buying and selling activity for Neuronetics.

STIM stock was purchased by a variety of institutional investors in the last quarter, including Quinn Opportunity Partners LLC, Two Sigma Investments LP, Two Sigma Advisers LP, DAFNA Capital Management LLC, Blair William & Co. IL, JPMorgan Chase & Co., GSA Capital Partners LLP, and BlackRock Inc.. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, Wilfred E Jaeger, and William Andrew Macan. View insider buying and selling activity for Neuronetics.

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $2.02.

Neuronetics has a market capitalization of $37.83 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe.

The official website for Neuronetics is www.neurostar.com.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]